在小鼠中复合人类环素A的药理动力学参数
Anastasiia Kalinina1, Elena Grigorieva1, Anna Smirnova1
1Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Kashirskoe sh. 24, 115478, Moscow, Russian Federation.
European journal of drug metabolism and pharmacokinetics
|December 1, 2023
概括
再组合的人类环素A (rhCypA) 在组织中迅速分布,在脏中积累并穿越血脑屏障. 这些在小鼠中的药理动力学发现支持对rhCypA疗法的潜在人类临床试验.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物治疗药物 生物治疗药物
- 免疫学 免疫学 免疫学
背景情况:
- 环素A (CypA) 是一种异构酶,具有护送和清洁功能.
- 分泌的CypA作为一种促炎因素,免疫调节剂,并影响抗瘤免疫力.
- 重组人类CypA (rhCypA) 显示出作为癌症,组织再生和神经疾病的生物治疗药物的潜力.
研究的目的:
- 在小鼠模型中分析复合人体环素A (rhCypA) 的药理动力学.
- 为了确定rhCypA.的生物分布和分泌模式.
- 为潜在的人类临床试验提供初步数据.
主要方法:
- 标有同位素125的I-rhCypA被用腹膜内或皮下给雌性小鼠.
- 使用一次剂量为100μg/小鼠,相当于估计的人类首次剂量.
- 通过对血液,内脏和尿液进行72小时的直接放射测量来评估生物分布和分泌.
主要成果:
- rhCypA 呈现出快速且均的组织分布.
- 脏表现出最高的热流和积累 (Cmax = 137-167 μg/g),表明它们是主要的分泌器官.
- 大脑和骨髓的热量最低,但保留时间最长 (MRT = 25-28小时),rhCypA穿过血脑屏障.
结论:
- rhCypA显示出有前途的器官特定积累和保留特征.
- 器官积累很可能是由受体表达介导的.
- 证明rhCypA能够穿越血脑屏障的能力是一项具有治疗意义的新发现.
相关概念视频
01:13Physiological Pharmacokinetic Models: Assumption with Protein Binding
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
01:30Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...